A GLOBAL LEADER IN EPIGENETICS

INVESTOR PRESENTATION
MADX: ORY
JANUARY 2018
LEGAL NOTICE

DISCLAIMER
This document has been prepared by Oryzon Genomics, S.A. exclusively for use during the presentation. Oryzon Genomics, S.A. does not assume liability for this document if it is used with a purpose other than the above. The information and any opinions or statements made in this document have not been verified by independent third parties; therefore, no express or implied warranty is made as to the impartiality, accuracy, completeness or correctness of the information or the opinions or statements expressed herein. Oryzon Genomics, S.A. does not assume liability of any kind, whether for negligence or any other reason, for any damage or loss arising from any use of this document or its contents. Neither this document nor any part of it constitutes a contract, nor may it be used for incorporation into or construction of any contract or agreement. Information in this document about the price at which securities issued by Oryzon Genomics, S.A. have been bought or sold in the past or about the yield on securities issued by Oryzon Genomics, S.A. cannot be relied upon as a guide to future performance.

IMPORTANT INFORMATION
This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of Law 24/1988, of 28 July, on the Securities Market, Royal Decree-Law 5/2005, of 11 March, and/or Royal Decree 1310/2005, of 4 November, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.

FORWARD-LOOKING STATEMENTS
This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Oryzon Genomics, S.A. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation is not an offer of securities for sale in the United States. The Company's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company's securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.
COMPANY HIGHLIGHTS

✓ MADX: ORY  A **publicly traded** company on the Spanish Stock Exchange

✓ A **clinical stage** biopharmaceutical company developing innovative therapies in the field of Epigenetics

✓ A competitive **EPIGENETIC Platform** validated scientifically and clinically

✓ Three therapeutic programs in LSD1 in development with multiple indication opportunities
  
  ✓ 1 in CNS  → in Phase IIA
  
  ✓ 1 in Oncology  → ready to start Phase II
  
  ✓ 1 in an orphan disease  → ready to start Phase I

✓ Large IP portfolio with technology fully developed in-house

✓ **Raised €32M** (in 2015-2016). Additional **18.2M€** raised from blue chip investors in the US and Europe **in March 2017**

✓ 33.48M Shares outstanding. Fully diluted. No warrants, no options

✓ **Cash runway** expected till 1Q2020

---

**ORYZON GENOMICS SA**
**BALANCE SHEET DATA (UNAUDITED)**
(Amounts in thousands US $)

<table>
<thead>
<tr>
<th></th>
<th>September 30th, 2017</th>
<th>September 30th, 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>39,841</td>
<td>25,900</td>
</tr>
<tr>
<td>Marquetable securities</td>
<td>200</td>
<td>6,248</td>
</tr>
<tr>
<td>Total Assets</td>
<td>69,741</td>
<td>56,564</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total Stockholders' equity</td>
<td>42,049</td>
<td>26,774</td>
</tr>
</tbody>
</table>

---

**Bolsa de Madrid**
A LSD1 focused company

3 Different LSD1 inhibitors in development

<table>
<thead>
<tr>
<th>MOLECULE</th>
<th>TARGET</th>
<th>INDICATION</th>
<th>DISCOVERY</th>
<th>H2L</th>
<th>LEAD OPTIMIZATION</th>
<th>PRECLINICAL</th>
<th>PHASE I</th>
<th>PHASE IIA</th>
<th>PHASE III</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORY-1001</td>
<td>LSD1</td>
<td>Leukemia (*)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Small Cell Lung Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORY-2001</td>
<td>LSD1-MAOB</td>
<td>Alzheimer's Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Parkinson's Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other Dementias</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORY-3001</td>
<td>LSD1</td>
<td>Undisclosed Indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other KDMs</td>
<td>Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other indications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other Epigenetic Targets</td>
<td>Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other indications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(*) Phase I/IIA in Acute Leukemia has been done in the same trial
HDACi improves HD symptoms in several animal models

HDAC2 inhibition recovers memory on the AD bi-tg CK-p25 Tg mouse model

HDAC inhibition improves FTD

HDAC inhibition improves MS in EAE models

HDAC2 cooperates with TFs as Sp3 in regulating Synaptic Function and Plasticity in Neurons

Identical twins (monozygotic)

Same DNA with GBA risk mutation

Disconcordant for symptoms of Parkinson’s

Up to 20 years difference in onset

Patient derived iPSCs: difference in MAO-B levels

LSD1 is a key component of different CNS Transcriptional complexes interacting with different Transcription Factors and very often with HDAC1 and HDAC2

Different to what happens in HDACs, it has been proven that it is possible to develop extremely selective LSD1 inhibitors with excellent pharmacological properties
ORY-2001 Summary

- A small molecule that selectively inhibits LSD1 and MAO-B
- Excellent Pharmacology. Safe in 9 months PC regulatory toxicological studies.
- Oral and Safe in humans in a Phase I trial with 106 healthy volunteers
- Crosses the BBB and engages the target in humans
- In Phase IIA (in a MS trial), other trials planned (AD)
- Biomarkers identified in animals that may be of use in human clinics
- Positive results in 7 different animal models and in many in-vitro models
- Produces positive results in:
  - Cognition
  - Neuroprotection
  - Neuroinflammation
  - Social Withdrawal
  - Aggression/Agitation
  - Others
- Capable of acting in all the processes that manifest in neurodegenerative disease patients
More than 200 SAMP8 mice treated with ORY-2001 in 10 different experiments showed memory rescue, a schematic overview below:

- **MILD**
  - Treatment from month 5 during 1 week
  - Treatment from month 6 during 1 month (Delayed start-1)
- **MODERATE**
  - Treatment from month 5 during 1 month, tested at month 7 (1 month after treatment cessation)
- **SEVERE**
  - Treatment from month 8 during 4 months (Delayed start-2)

Results suggestive of Disease modifying potential
Up-regulation of the synaptic plasticity genes in hippocampus by ORY-2001

Down-regulation by ORY-2001 of the pro-inflammatory genes as S100A9. This protein in hippocampus is particularly interesting, since S100A9 is emerging as an important contributor to inflammation-related neurodegeneration.

S100A9 was found to be increased in patients with AD, postoperative cognitive dysfunction (POCD), traumatic brain injury (TBI), and in neuroinflammatory diseases like MS and others.

Anti-neuroinflammatory results are not constrained to this experimental model.
ORY-2001 reduces the expression of genes involved in neuroinflammation

- ORY-2001 down-regulates genes associated with inflammation including S100A9 and T-cell receptor b chains that can be found over-expressed in SAMP-8 mice.
- In more specific models of inflammation, ORY-2001 protects the brain and CNS from acute inflammatory stress, as shown in the EAE model where immune infiltration in the spinal cord is greatly reduced, demyelination is avoided and the clinical score is greatly reduced.
- ORY-2001 also provides protection in other murine models with induced demyelinating disease.
ORY-2001 is more protective and/or acts faster than Fingolimod in the effector phase of the EAE model.

Effects of ORY-2001 and FTY720 (fingolimod) in the EAE effector phase (therapeutic setting):

- ORY-2001 clearly reduced the mean clinical score, FTY720 exhibited only a tendency.
- ORY-2001 is more effective and/or faster acting than FTY720 in the effector phase.
In Alzheimer’s and other neurodegenerative disorders, cognitive decline is often accompanied by aggressiveness, agitation, psychosis, depression, social withdrawal and apathy.

The post-weaning social isolation rat model of neurodevelopmental deficits was used to further assess ORY-2001 effects on behavior.

In this rat model, isolation after the weaning resulted in higher social avoidance. Treatment with ORY-2001 reverted this effect, normalizing the social interaction behavior.
Unplanned observations revealed that SAMP8 male mice treated with ORY-2001 (bottom mouse) presented a better condition than untreated animals (top mouse) suggesting that ORY-2001 might reduce the aggressions between males caged together.

In AD patients, cognitive decline is often accompanied by aggressiveness.

Using the Resident-Intruder test, social behavior was evaluated in SAMP8 mice:

- SAMP8 animals showed higher aggressive behavior than SAMR1 animals, and ORY-2001 treatment significantly reduced aggression parameters and restored to levels equivalent to control SAMR1 mice.
ORY-2001 confers neuroprotection

Glutamate excitotoxicity

- ORY-2001 treatment protects against chronic glutamate excitotoxicity in organotypic spinal medulla explants exposed to THA, a potent glutamate transporter inhibitor, a classical model of Amyotrophic Lateral Sclerosis (ALS).

- There is evidence for chronic excitotoxicity in human patients of AD which may be driven by multiple factors including the sensitization of NMDA receptors, a decrease in L-glu and L-asp reuptake capacity and an increase in glutamate release via system $x_c^{-}$.
The Questions we wanted to answer

1. Epigenetic drugs often have pleiotropic effects resulting in side effects
2. Epigenetic drugs often have a hematological impact, eventually producing neutropenia and thrombocytopenia
3. Drugs for CNS need to demonstrate brain penetrance and target engagement

The Clinical Trial CL01-ORY-2001 was designed to address all these concerns

---

**Phase I, single center, double blind, parallel, ascending single and multiple dose trial.**

**TITLE:** A Study to Assess the Safety, Tolerability and Pharmacokinetic of Single and Multiple Oral Doses of ORY-2001 in Healthy Male, Female Subjects and Elderly Population  
**STUDY CODE:** CL01-ORY-2001  
**EUDRACT NUMBER:** 2015-003721-33

**Phase I Clinical Trial** in young and elderly healthy volunteers

---

**A Phase I study with 106 healthy volunteers, young and elderly**
CL01-ORY-2001 Phase I: Safety and Hematology

- Orally administered ORY-2001 is safe and well tolerated.
- ORY-2001 did not provoke significant clinical or laboratory changes or adverse events in the MAD up to 2.5 mg. Single and multiple ascending doses were hematologically safe.
- An additional cohort was requested in an amendment to model the PK/PD ratios.
- PK-PD modelling allows us to establish a safe administration scheme for long term efficacy studies of ORY-2001 in Phase II trials.

Final data of Phase I on ORY-2001 were presented at AAIC-2017 London (July-2017)
**ORY-2001 PHASE I CLINICAL TRIAL CONCLUSIONS**

- **Elderly cohort** Safety data comparable to young healthy volunteers
- **PK** Oral PK T1/2 ≈ 22h allowing once daily oral
- **ORY-2001 efficiently crosses the BBB:**
  - ORY-2001 concentrations measured in CSF at 2, 6 and 12 h after a single oral 2 mg or 4 mg dose
  - CSF levels comparable to corresponding unbound plasma concentrations (CSF/plasma_u ratio ≈ 0.7-0.9)
- **ORY-2001 efficiently inhibits the brain human LSD1**

<table>
<thead>
<tr>
<th>Time</th>
<th>CSF/plasma_u ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SAD 2 mg</td>
</tr>
<tr>
<td>2 h</td>
<td>0.78</td>
</tr>
<tr>
<td>6 h</td>
<td>0.74</td>
</tr>
<tr>
<td>12 h</td>
<td>0.92</td>
</tr>
<tr>
<td>Cmax</td>
<td>0.64</td>
</tr>
</tbody>
</table>
ORY-2001: next two Phase IIa studies ready to start

SATEEN  A pilot study in MS

SAfety, Tolerability and Efficacy in an EPIGENETIC approach to treat Multiple Sclerosis

Randomised, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)

APPROVED by the AEMPS (October 30th)

Spain only; 4 Hospitals; 24 patients (RR & SP);

FPI expected Jan 2018; LPO December 2018
A multicenter, multinational, randomized, double-blind, placebo-controlled, 3-arm, 26 weeks parallel-group study to evaluate the safety, tolerability of ORY-2001 in patients with mild-moderate AD

**Design:** This Phase IIa study is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study conducted in 90 patients (male and female, aged 50 to 85 years) with mild to moderate AD. The safety, tolerability and clinical effects of two doses of ORY-2001 vs placebo, in a 2:2:1 ratio (36/36/18), will be evaluated in these patients. The study will consist of a screening period and a 26 week double-blind, placebo-controlled treatment period with an open-label extension period of 26 weeks.

**Population:** No. of patients: **90**
Randomization: 2/2/1
2 dose ORY-2001 arms (36/36) and one placebo(18)

**Sites:** 12-15 Sites

**Clinical Study Time Frame:**
- First patient in: 1Q 2018
- Last patient last visit: 1Q 2019
- Study end: 4Q 2019
Outcome measures:

Primary endpoint:
- Frequency and severity of adverse events

Exploratory endpoints:
- Cognitive: MMSE, ADAS-cog 14, Cogstate battery
- Functional: CDR-SB, Dependence scale
- Other Functional and behavioural Tests
- Biomarkers: MRI, CSF (AD, Novel e.g. S100A9, YKL40) and other CSF and peripheral biomarkers
ORY-1001
LSD1 inhibitors in Cancer

SUMMARY
LSD1 is a key effector of the differentiation block in MLL leukemia

MLL Leukemic stem cells are addicted to LSD1 activity

23 murine MLL leukemias
Known AML-CFC
% blast-like (Type 1) ≈ LSC potential

GE analysis
Top epigenetic factor: LSD1
ORY-1001 was well tolerated. Predicted toxicities were thrombocytopenia & anaemia. The great majority of AEs and SAEs were likely related to the underlying disease and not to drug.

AEs observed at the MTD were: Lung infections, Severe fatigue, Erythema nodosum.

Results of the study suggest a maximum tolerated dose of 220 μg/m²/d, the SMC recommended a dose of 140 μg/m²/d for future studies.

Excellent oral bioavailability in humans and pharmacokinetic parameters well established.

1 CRi and 5 patients showed hints of clinical response at cohorts 3, 5, 6 and 7.
55% blast reduction from baseline in patient 0701 (MLL-AF M4)

Baseline = 97% BM blasts

Post ORY-1001 2 cycle treatment = **55% blast reduction**

Granulocytic differentiation = 28%
Preliminary data presented at ASH 2016.

- ORY-1001 was administered to 41 patients
- Excellent oral bioavailability in humans and excellent PK parameters
- Pharmacodynamic biomarkers (MLLr) permit monitoring of response to ORY-1001 in M4/M5 AML patients
- 22% (6/27) response rate in the phase 1 portion, including one CRi (complete remission with incomplete blood count recovery)
- 46% (6/13) of relapsed/refractory AML patients showed anti-leukemic clinical activity in extension arm
- Partial bone marrow remission in 50% (2/4) M6 patients, suggesting disease stabilization
- 100% (5/5) of MLL gene fusion patients with evaluable PD samples showed evidence of blast differentiation by qRT-PCR analysis
- 67% (4/6) of MLL leukemia patients showed evidence of morphological blast cell differentiation (2 patients experienced a differentiation syndrome)
- 15% (2 (M6)/13) partial bone marrow responses and 1 MLL patient with 3 month hematologic improvement

From all patients in the phase 1/2a study, antileukemic activity observed in 29% of patients (12/41), including one CRi
LSD1 in Small Cell Lung Cancer (SCLC)

- LSD1 inhibition alone can stop tumor progression in NCI-H1417 SCLC xenograft
- Combination of ORY-1001 with SOC Improves Potency and Duration Response in H526 Model

![Graph showing tumor progression and response to treatments](image-url)
ORY-1001 PDX-SCLC xenografts

- Response to ORY-1001 in PDX models of SCLC is variable, but some are very strong.

- FHSC04 model: derived from a SCLC patient who relapsed after first line therapy.

- 6/10 FHSC04 mice treated with ORY-1001 did not show relapse after 300 days.
ORY-1001 in SCLC and next clinical development

- Oryzon licensed ORY-1001 global rights to Roche (2014)
- In January 2017 an exploratory Phase I study of RG6016 (ORY-1001) was started in small cell lung cancer (SCLC). This clinical trial has been executed by ROCHE
- ORYZON has regained rights on ORY-1001 in January 2018 as a consequence of Roche’s reprioritization portfolio
- Oryzon to continue clinical development of ORY-1001
- In SCLC, we anticipate to introduce stratification of patients using biomarkers

- A new Phase I/IIa in SCLC is in preparation
- A follow on Phase IIa in AML- MDS in combination with other agents is under preparation

Anticipated Start for both 1H 2018
1. Phase I Final Data (AAIC-2017 London)
2. Filing CTA / IND for Phase IIA in MS
4. Presentation of Phase IIA plans in AD (CTAD-2017 Boston)
5. Additional Preclinical Data of ORY-2001 in animal models of other human CNS conditions (SFN2017)
6. Anticipated FPI in a Phase IIA study in MS
7. Anticipated FPI in a Phase IIA study in AD
8. Phase IIA Prelim read outs in MS
9. Phase IIA Prelim read outs in AD
On October 31st 2017, Oryzon Genomics had 2,241 shareholders.

- The 45.46% of the shares are owned by the reference shareholders.

- All the Company shares are common shares, without any additional options or warrants.

### Capitalization and ownership summary

<table>
<thead>
<tr>
<th>TOP 10 ORYZON SHAREHOLDER</th>
<th>by October 31st 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAJETI CAPITAL SA</td>
<td>7,017,799 20,54%</td>
</tr>
<tr>
<td>TAMARA MAES</td>
<td>3,742,530 10,96%</td>
</tr>
<tr>
<td>CARLOS MANUEL BUESA</td>
<td>3,742,530 10,96%</td>
</tr>
<tr>
<td>ARRIENDOS VENFERCA, SL</td>
<td>2,004,723 5,87%</td>
</tr>
<tr>
<td>JOSE MARIA ECHARRI</td>
<td>1,026,928 3,01%</td>
</tr>
<tr>
<td>MINORITY SHAREHOLDERS</td>
<td>16,626,881 48,67%</td>
</tr>
<tr>
<td>TOTAL COMPANY SHARES</td>
<td>34,161,391</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Shareholder</th>
<th>Shares</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference Shareholder</td>
<td>4 15,529,787</td>
<td>45,46%</td>
</tr>
<tr>
<td>Oryzon Genomics (Own Shares)</td>
<td>1 668,587</td>
<td>1,96%</td>
</tr>
<tr>
<td>Shareholder &gt;3%</td>
<td>1 2,004,723</td>
<td>5,87%</td>
</tr>
<tr>
<td>Shareholder between 1% &amp; 3%</td>
<td>6 3,008,833</td>
<td>8,81%</td>
</tr>
<tr>
<td>Other Shareholder &lt;1%</td>
<td>2,229 12,949,461</td>
<td>37,91%</td>
</tr>
<tr>
<td>TOTAL</td>
<td>2,241 34,161,391</td>
<td>100%</td>
</tr>
</tbody>
</table>

% Shareholders distribution:
- Reference Shareholder: 45%
- Oryzon Genomics (Own Shares): 2%
- Shareholder >3%: 6%
- Shareholder between 1% & 3%: 9%
- Other Shareholder <1%: 38%
- TOTAL: 100%
ORYZON
A GLOBAL LEADER
IN EPIGENETICS

CARLOS BUESA
CEO & President
cbuesa@oryzon.com

TAMARA MAES
CSO
tmaes@oryzon.com

ROGER BULLOCK
CMO
rbullock@oryzon.com

EMILI TORRELL
BDO
etorrell@oryzon.com